Aurobindo Pharma share price declined in the opening trade on September 8 following the company received eight observations from the United States Food and Drug Administration (USFDA).
At 09:25am, Aurobindo Pharma was quoting at Rs 1,036.60, down Rs 7.80, or 0.75 percent, on the BSE.
The USFDA inspected company's Unit-XII, including oral solids and injectable manufacturing unit, situated at Bachupally, Medchal Malkajgiri District, Telangana from August 25 to September 05, 2025.
At the end of the current inspection, a ‘Form 483’ was issued with a total of 8 observations for both (oral solids & injectable).
All observations are procedural in nature and will respond to the US FDA within the stipulated timelines, company said.
Catch all the market action on our live blog
On August 29, the USFDA issued a Form 483 with five observations on inspecting Unit-I, an API manufacturing facility of the company’s subsidiary Apitoria Pharma at Sangareddy, Telangana, during August 21–29.
The observations were procedural in nature, and no data integrity issues were reported.
The share touched a 52-week high of Rs 1,592.55 and a 52-week low of Rs 994.35 on 13 September, 2024 and 07 April, 2025, respectively.
Currently, the stock is trading 34.91 percent below its 52-week high and 4.25 percent above its 52-week low.
The market capitalisation of the company stands at Rs 60,205.90 crore.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
